Natco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent version of AstraZeneca’s Lynparza. The drug addresses a $1.4-billion U.S. market opportunity. The company will manufacture the product, while Alembic Pharmaceuticals will handle its U.S. commercialisation.
Risk Disclosure: Trading in financial instruments and/or digital currencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of digital currencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or digital currencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Super-reviews.co would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Super-reviews.co and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Super-reviews.co and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Super-reviews.co may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003 | Terms and conditions | Privacy Policy